×
About 49,123 results

ALLMedicine™ Hepatitis B Center

Research & Reviews  16,097 results

Antibody response to an accelerated course of Hepatitis B vaccination.
https://doi.org/10.1093/occmed/kqac054
Occupational Medicine (Oxford, England); Lian PCS, Morrish B

Aug 7th, 2022 - There are several courses with different dosing intervals for Hepatitis B vaccination. This independent study is looking at the antibody response after three doses of the accelerated course. The primary aim of the study was to examine data availab...

Efficacy and safety of Fuzheng Huayu tablet on persistent advanced liver fibrosis follo...
https://doi.org/10.1016/j.jep.2022.115599
Journal of Ethnopharmacology; Zhao ZM, Zhu CW et. al.

Aug 7th, 2022 - Antiviral therapy can alleviate liver fibrosis in chronic hepatitis B, but it has a limited effect on advanced liver fibrosis/cirrhosis. Traditional Chinese medicine (TCM), particularly FuZheng HuaYu (FZHY) tablet, appears to have an antifibrotic ...

Awareness and treatment of chronic hepatitis B in Malaysia-findings from a community-ba...
https://doi.org/10.1186/s12876-022-02458-9
BMC Gastroenterology; Lim ZZ, Teo JS et. al.

Aug 7th, 2022 - In 2016 the World Health Organization (WHO) had adopted a global strategy to eliminate Hepatitis B (HBV) by 2030 through five core interventions. One of which is the "cascade of care", the continuum of services that persons with chronic Hepatitis ...

The in vitro replication phenotype of hepatitis B virus (HBV) splice variant Sp1.
https://doi.org/10.1016/j.virol.2022.07.005
Virology Sozzi V, McCoullough L et. al.

Aug 6th, 2022 - Although not critical for hepatitis B virus (HBV) replication, splicing of HBV pre-genomic RNA generates multiple HBV splice variants, some of which have been shown to impact replication of the genome-length HBV on which they rely for their replic...

Clinical and Immunological Defects and Outcomes in Patients with Chromosome 22q11.2 Del...
https://doi.org/10.1007/s10875-022-01340-3
Journal of Clinical Immunology; Yu HH, Chien YH et. al.

Aug 5th, 2022 - Chromosome 22q11.2 deletion syndrome (22q11.2DS) is the most common microdeletion syndrome in humans and can present with highly variable clinical manifestations. Immune deficiencies occur because of thymic hypoplasia or aplasia. This retrospectiv...

see more →

Guidelines  46 results

KASL clinical practice guidelines for management of chronic hepatitis B.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013624
Clinical and Molecular Hepatology;

Apr 18th, 2022 - KASL clinical practice guidelines for management of chronic hepatitis B.|2022| ,|therapeutic use,genetics,drug therapy,

Universal Hepatitis B Vaccination in Adults Aged 19-59 Years: Updated Recommendations o...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979596
MMWR. Morbidity and Mortality Weekly Report; Weng MK, Doshani M et. al.

Apr 1st, 2022 - Hepatitis B (HepB) vaccines have demonstrated safety, immunogenicity, and efficacy during the past 4 decades (1,2). However, vaccination coverage among adults has been suboptimal, limiting further reduction in hepatitis B virus (HBV) infections in...

NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF CHRONIC INFECTION WITH HEPATITIS B VIRUS.
https://doi.org/10.1016/j.clinre.2021.101773
Clinics and Research in Hepatology and Gastroenterology; Leroy V, Chevaliez S et. al.

Aug 1st, 2021 - Diagnosis of chronic hepatitis B virus (HBV) infection, initial staging of infection and monitoring of treated and untreated patients are mainly based on clinical, biological and imaging criteria allowing a complete non-invasive management for the...

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Managemen...
https://doi.org/10.1002/art.41776
Arthritis & Rheumatology (Hoboken, N.J.); Chung SA, Gorelik M et. al.

Jul 9th, 2021 - To provide evidence-based recommendations and expert guidance for the management of systemic polyarteritis nodosa (PAN). Twenty-one clinical questions regarding diagnostic testing, treatment, and management were developed in the population, interv...

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Managemen...
https://doi.org/10.1002/acr.24633
Arthritis Care & Research; Chung SA, Gorelik M et. al.

Jul 9th, 2021 - To provide evidence-based recommendations and expert guidance for the management of systemic polyarteritis nodosa (PAN). Twenty-one clinical questions regarding diagnostic testing, treatment, and management were developed in the population, interv...

see more →

Drugs  143 results see all →

Clinicaltrials.gov  1,754 results

Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of PA1010 in HBV Patients
https://clinicaltrials.gov/ct2/show/NCT05019040

Aug 5th, 2022 - This is a multicenter, randomized, open-label, controlled, dose-escalation clinical trial, the objective is to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of PA1010 tablets in Chinese patients with Chroni...

A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus
https://clinicaltrials.gov/ct2/show/NCT04535544

Aug 3rd, 2022 - JNJ-73763989 is a liver-targeted antiviral therapeutic for subcutaneous injection designed to treat chronic hepatitis B virus (HBV) infection via ribonucleic acid interference mechanism. This phase 2 study is designed to evaluate safety and effica...

A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic He...
https://clinicaltrials.gov/ct2/show/NCT04439539

Aug 3rd, 2022 - Hepatitis B virus (HBV) is a small deoxyribonucleic acid virus that specifically infects the human liver. The acute phase of infection is either followed by an immune controlled state or progresses to chronic hepatitis B. The worldwide estimated p...

A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection
https://clinicaltrials.gov/ct2/show/NCT04585789

Aug 3rd, 2022 - The title of protocol reflects the original study design. The study design section is reflecting that the design as of protocol amendment 5 is non-randomized.

Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas
https://clinicaltrials.gov/ct2/show/NCT04952584

Aug 3rd, 2022 - Earlier, healthy donors gave blood for us to make CD30.CAR-EBVST cells in the laboratory. These cells were grown and frozen and the investigators will select the donor which the investigators think is the best match for the patient. This is a dose...

see more →

News  1,573 results

US Administers Over 7300 Novavax Vaccine Doses: CDC
https://www.medscape.com/viewarticle/978706

Aug 8th, 2022 - (Reuters) - The United States has administered more than 7,300 doses of Novavax Inc's COVID-19 shot, which health officials hope will convince more people to opt for vaccinations as it is based on a technology that has been in use for decades. Ove...

EU Says Novavax COVID Shot Must Carry Heart Side Effect Warning
https://www.medscape.com/viewarticle/978527

Aug 4th, 2022 - LONDON (Reuters) -The European Medicines Agency (EMA) is recommending Novavax's COVID-19 vaccine carry a warning of the possibility of two types of heart inflammation, an added burden for a shot that has so far failed to win wide uptake. The heart...

Landmark ALLIANCE Results Offer Tenofovir Guidance in HIV/HBV Co-infection
https://www.medscape.com/viewarticle/978432

Aug 2nd, 2022 - Interim results of ALLIANCE, the first head-to-head trial comparing two different tenofovir-containing antiretroviral regimens for the treatment of HIV and hepatitis B (HBV) co-infection, demonstrate the superiority of bictegravir/emtricitabine/te...

Commentary: HCC With HCV and Treatment Comparisons for Unresectable HCC, August 2022
https://www.mdedge.com/gihepnews/article/256598/hepatocellular-carcinoma/commentary-hcc-hcv-and-treatment-comparisons

Jul 29th, 2022 - Nevena Damjanov, MD Systemic therapy is frequently prescribed for patients with unresectable hepatocellular carcinoma (HCC). Not all studies of systemic therapies have been able to demonstrate a survival benefit, but several treatments have been s.

Statin use ties with lower HCC risk in dialysis patients with HBV or HCV monoinfection
https://www.mdedge.com/gihepnews/article/256537/hepatocellular-carcinoma/statin-use-ties-lower-hcc-risk-dialysis-patients

Jul 27th, 2022 - Key clinical point: Statin use is associated with a lower risk for hepatocellular carcinoma (HCC) incidence in dialysis patients with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. Major finding: Statin users vs nonusers ha.

see more →

Patient Education  36 results see all →